Phosphodiesterase 4 inhibitors for the treatment of COPD.

Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3',5'-monophosphate-metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and pulmonary nerves. Selective inhibitors of this enzyme have been available for a number of years and show a broad spectrum of activity in animal models of COPD and asthma. The class-associated side effects, mainly nausea and emesis, appear to have been at least partially overcome by the so-called "second-generation" PDE4 inhibitors. Currently, three companies are in the later stages of development of candidate second-generation PDE4 inhibitors for the treatment of COPD patients. The preclinical profile of one of these, BAY 19-8004, is summarized below. The initial clinical data on the most advanced compound, cilomilast, were indeed encouraging. However, full knowledge of the therapeutic value of this novel compound class awaits the outcome of longer term clinical trials.

[1]  W. Maziak,et al.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[2]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[3]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[4]  P. Jeffery,et al.  Structural and inflammatory changes in COPD: a comparison with asthma. , 1998, Thorax.

[5]  M. Teixeira,et al.  Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? , 1997, Trends in pharmacological sciences.

[6]  Burge Ps.  EUROSCOP, ISOLDE and the Copenhagen City Lung Study , 1999 .

[7]  F. Dallegri,et al.  Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: role of intracellular cyclic AMP levels. , 1998, Experimental hematology.

[8]  S. Christensen,et al.  Suppression of human inflammatory cell function by subtype‐selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B , 1999, British journal of pharmacology.

[9]  A. Marfat,et al.  Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. , 1996, Journal of medicinal chemistry.

[10]  A. Hara,et al.  Inhibition of tumor necrosis factor-alpha induced neutrophil apoptosis by cyclic AMP: involvement of caspase cascade. , 1999, European journal of pharmacology.

[11]  R. Horowski,et al.  Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports , 1985 .

[12]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[13]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.